Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)”In the company’s words, NCT05065619 on ClinicalTrials.gov
- Tested for
- SARS-CoV-2 Infection
- Main trialPhase 1/2
- “The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.”In the company’s words, NCT05065619 on ClinicalTrials.gov
- Other names
- CoVLP · AS03 adjuvant
Other drugs for SARS-CoV-2 Infection
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 12 Mar 2022 | Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026